TB500: Side Effects

Safety Notice#

The safety profile of TB500 (Thymosin Beta-4) in humans is based on limited but encouraging clinical trial data. Phase I studies in healthy volunteers demonstrated a favorable safety profile at doses up to 1260 mg administered intravenously. However, long-term safety data from controlled clinical trials is not available, and the information below should be interpreted in the context of these limitations.

Clinical Trial Safety Data#

Phase I Trial in Western Populations#

The most comprehensive safety data for TB500 comes from a randomized, placebo-controlled phase I trial conducted by Allan and colleagues. In this study, 40 healthy volunteers were randomized across four dose cohorts (42, 140, 420, and 1260 mg) receiving single and multiple intravenous doses of synthetic Thymosin Beta-4 for 14 days.

Key safety findings included:

• No dose-limiting toxicities were observed at any dose level
• No serious adverse events were reported in any treatment group
• Adverse events were infrequent and mild to moderate in intensity
• No clinically significant changes in laboratory values, vital signs, or ECG parameters
• No evidence of immunogenicity (anti-drug antibody formation)

The study concluded that synthetic Thymosin Beta-4 given intravenously as single or multiple daily doses over a dose range of 42-1260 mg was well tolerated with no evidence of dose-limiting toxicity.

Phase I Trial in Chinese Volunteers#

A first-in-human study of recombinant human Thymosin Beta-4 (rhTβ4) conducted in healthy Chinese volunteers confirmed the favorable safety profile. This randomized, double-blind study tested single ascending doses and multiple doses administered intravenously. The results were consistent with the Western population study:

• No dose-limiting toxicities were observed
• No serious adverse events were reported
• Adverse events were mild to moderate in intensity
• The peptide was well tolerated across all dose levels

Ophthalmic Safety Data#

Topical Thymosin Beta-4 (RGN-259, 0.1% ophthalmic solution) demonstrated an excellent ocular safety profile in phase II and III clinical trials for dry eye disease and neurotrophic keratopathy. No significant ocular adverse events attributable to the drug were reported. Mild and transient ocular discomfort upon instillation was the most commonly noted effect.

Preclinical Toxicology#

Acute Toxicity#

Acute toxicology studies in rodents and dogs established a wide safety margin for Thymosin Beta-4. No significant toxicity was observed at doses substantially higher than those planned for clinical use. The LD50 was not reached in standard acute toxicity protocols, indicating very low acute toxicity potential.

Chronic and Subchronic Studies#

Repeat-dose toxicology studies of up to 28 days duration in rats and dogs showed no treatment-related adverse findings at multiple dose levels. No organ toxicity, hematological abnormalities, or pathological changes were attributed to Thymosin Beta-4 administration. These studies supported the initiation of human clinical trials.

Reproductive Toxicity#

Formal reproductive and developmental toxicity studies have not been published for Thymosin Beta-4. Given that Tβ4 is a naturally occurring peptide expressed throughout embryonic development and plays roles in cardiac morphogenesis, the effects of exogenous administration during pregnancy are unknown. As a precaution, TB500 should be avoided during pregnancy and breastfeeding.

Theoretical Safety Concerns#

Angiogenesis and Cancer Risk#

The most frequently discussed theoretical safety concern is the potential for Thymosin Beta-4 to promote tumor growth through its angiogenic and cell-migratory properties. Tβ4 is overexpressed in some tumor types, and its ability to promote new blood vessel formation could theoretically support tumor vascularization. However, the relationship between Tβ4 and cancer is complex:

• Some studies suggest Tβ4 overexpression correlates with tumor aggressiveness and metastatic potential
• Other research indicates Tβ4 may have tumor-suppressive effects in certain contexts
• No clinical evidence directly links exogenous Tβ4 administration to cancer development
• The short duration of typical TB500 research protocols may not capture long-term oncological risks

Until this question is resolved through long-term studies, TB500 should be avoided by individuals with active malignancy, a history of cancer, or strong genetic predisposition to cancer.

Immune Modulation#

Thymosin Beta-4 has documented immunomodulatory effects, including modulation of NF-kB signaling and cytokine expression. While these effects are generally anti-inflammatory and may be beneficial in many contexts, they could theoretically interfere with immune surveillance against infections or malignancy in immunocompromised individuals.

Fibrosis and Tissue Remodeling#

While Tβ4 generally demonstrates anti-fibrotic effects, its promotion of cell migration and tissue remodeling raises theoretical concerns about aberrant tissue growth in certain pathological contexts. No such adverse effects have been observed in clinical studies to date.

Drug Interactions#

ACE Inhibitors#

The interaction between TB500 and ACE inhibitors is the most pharmacologically plausible drug interaction. The Tβ4 metabolite Ac-SDKP is normally degraded by angiotensin-converting enzyme. In patients taking ACE inhibitors (such as enalapril, lisinopril, or ramipril), ACE activity is reduced, which leads to elevated plasma levels of Ac-SDKP. Concurrent administration of TB500 could further increase Ac-SDKP levels, potentially amplifying its anti-fibrotic and anti-proliferative effects on cardiac fibroblasts and hematopoietic stem cells. While this interaction has not been studied directly, monitoring for enhanced anti-fibrotic effects is advisable.

Anticoagulants and Antiplatelet Agents#

Thymosin Beta-4 is released from activated platelets during the coagulation cascade and plays a role in platelet function. Theoretical interactions with anticoagulants (warfarin, heparin, DOACs) and antiplatelet agents (aspirin, clopidogrel) cannot be excluded, though no adverse interactions have been reported. Patients on anticoagulant therapy should exercise caution and inform their healthcare provider.

Immunosuppressive Medications#

Given Tβ4's immunomodulatory properties, concurrent use with immunosuppressive agents (corticosteroids, calcineurin inhibitors, biologics) could result in unpredictable immune effects. No formal interaction studies have been conducted.

Monitoring Recommendations#

For research contexts involving TB500, the following monitoring parameters are suggested based on its known pharmacological profile:

• Baseline and periodic: Complete blood count, comprehensive metabolic panel, coagulation studies
• Cardiovascular: Blood pressure, heart rate, ECG (particularly in cardiac research applications)
• Injection site: Assess for local reactions, signs of infection
• Oncology screening: Age-appropriate cancer screening prior to and during prolonged use
• Immune function: If concurrent immunosuppressive therapy, periodic immune function assessment

Evidence Gaps in Safety Data#

• No published data on safety beyond 14 consecutive days of dosing in humans
• Long-term oncological safety has not been assessed in prospective human studies
• Drug-drug interaction studies have not been conducted
• Safety in special populations (elderly, hepatic impairment, renal impairment) has not been characterized
• Reproductive and developmental toxicity data is lacking
• Immunogenicity with chronic dosing has not been evaluated
• Safety of subcutaneous administration (the most common research route) has not been formally studied in clinical trials

Related Reading#

• TB500 overview and research guide
• TB500 dosing protocols
• TB500 risks and legal status